NCT05774171 is a clinical trial of no intervention in COVID-19 Infection, sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences.

Who is sponsoring NCT05774171?

NCT05774171 is sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences.

What drugs are being tested in NCT05774171?

Interventions in NCT05774171: no intervention.

What condition does NCT05774171 study?

NCT05774171 studies COVID-19 Infection, COVID-19 Vaccine.

Is NCT05774171 still recruiting?

NCT05774171 is currently status unknown. Last updated 17 March 2023.

Last reviewed 2023-03-17 · How we verify

NCT05774171

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

To Explore the Protective Effect of SARS-CoV-2 Vaccination on Cancer Patients Infected With SARS-CoV-2

Status unknown Last updated 17 March 2023

What this trial tests

trial testing no intervention in COVID-19 Infection in 700 participants. Status unknown.

Timeline

1 January 2023

Primary endpoint
31 December 2023

31 December 2023

Quick facts

Lead sponsor	Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	700
Start date	1 January 2023
Primary completion	31 December 2023
Estimated completion	31 December 2023
Sites	1 location across China

Drugs / interventions tested

no intervention

Conditions studied

COVID-19 Infection — all drugs for COVID-19 Infection →
COVID-19 Vaccine — all drugs for COVID-19 Vaccine →

Sponsor

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Who can join

Adults 18 to 90, any sex, with COVID-19 Infection or COVID-19 Vaccine. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

For tumor patients, the virus antibody titer produced by the SARS-CoV-2 vaccine is often lower than that of normal people in a short period of time, but in the long run, it can significantly reduce the infection rate and fatality rate of the new coronavirus, and the adverse reactions are mild and there is no significant difference with normal people. However, there is still no real-world research data in China to prove the protective effect of the SARS-CoV-2 vaccine on patients with tumors infected with the SARS-CoV-2 virus.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Vaccines for preventing infections in adults with solid tumours.
Hirsch C, Zorger AM, Baumann M, Park YS, et al · · 2025 · cited 3× · PMID 40237463 · DOI 10.1002/14651858.cd015551.pub2

Verify or expand the search:

Other trials of no intervention

Trials testing the same drug.

NCT07480057 — Assessment of Changes in Bone Mineral Metabolism After Liver Transplantation by Bone Mineral Densitometry · recruiting
NCT07253506 — Turkish Adaptation, Validity, and Reliability Study of the Patient Experience With Treatment and Self-Management Scale i · not yet recruiting
NCT07253519 — The Relationship Between Mood and Insomnia Severity and Caregiver Burden in Caregivers of Stroke · not yet recruiting
NCT07194096 — Stress Hyperglycemia Ratio and Postoperative Delirium · not yet recruiting
NCT07240337 — Botulinum Toxin Applications in Hemiplegic Patients · recruiting

Other recruiting trials for COVID-19 Infection

Currently open trials in the same condition.

NCT07013474 — A Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised · Phase 3 · recruiting
NCT06965751 — A Study on the Effects in Healthy People of a New Drug Called PDI204 for Treating COVID-19 · Phase 1 · active not recruiting
NCT06923137 — A Study to Learn About How Well Yearly Updates to the COVID-19 Vaccine Work to Protect People From COVID-19 and How Much · active not recruiting
NCT05672355 — A Vaccine Booster (GEO-CM04S1) for the Prevention of COVID-19 in Patients With Chronic Lymphocytic Leukemia · Phase 2 · recruiting
NCT05774093 — Evaluation of COVID-19 Immune Barrier and Reinfection Risk · recruiting

Other Cancer Institute and Hospital, Chinese Academy of Medical Sciences trials

Trials by the same sponsor.

NCT07531563 — Protein Supplementation for Radiation- Induced Oral Mucositis in Head and Neck Cancer Patients Receiving Radiotherapy · NA · not yet recruiting
NCT07537049 — BR101 in Patients With Relapsed/Refractory Multiple Myeloma · Phase 1 · not yet recruiting
NCT07187154 — The Application of Symptoms Management Program Based on the Patient Reported Outcome After Esophagectomy · NA · not yet recruiting
NCT07530549 — A Phase II Single-arm Clinical Study in the Treatment of Locally Advanced Esophageal Cancer After Failed Neoadjuvant Che · Phase 2 · not yet recruiting
NCT07507058 — Hypofractionated Radiotherapy for Postoperative Intermediate-Risk Head and Neck Squamous Cell Carcinoma · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05774171 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Last refreshed: 17 March 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05774171.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing